Clinical Trial

Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Name: Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer — clinical trial record (NCT07523763)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NIVO1002024

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Patients with clinical stage II-III dMMR/MSI colorectal adenocarcinoma will be treated with low-dose immunotherapy: nivolumab 100 mg or pembrolizumab 100 mg. The duration of treatment is 6 months.

Protocol Amendment History 1 change

minor Trial arms changed: 1 -> 2 2026-04-18

Trial Details

NCT Number	NCT07523763
Lead Sponsor	Blokhin's Russian Cancer Research Center
Conditions	Colorectal Cancer (MSI-H), Colorectal Cancer (CRC)
Enrollment	30 participants
Start Date	2024-03-22
Primary Completion	2025-12-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-17